Routila, JohannesBilgen, TürkerSaramaki, OutiGrenman, ReidarVisakorpi, TapioWestermarck, JukkaVentela, Sami2022-05-112022-05-1120160904-25121600-0714https://doi.org/10.1111/jop.12372https://hdl.handle.net/20.500.11776/10603BackgroundCIP2A, an inhibitor of PP2A tumour suppressor function, is a widely overexpressed biomarker of aggressive disease and poor therapy response in multiple human cancer types. MethodsCIP2A and DPPA4 copy number alterations and expression were analysed by fluorescence in situ hybridisation (FISH) and immunohistochemistry (IHC) in different cell lines and a tissue microarray of 52 HNSCC patients. Results were correlated with patient survival and other clinicopathological data. ResultsCIP2A and DPPA4 copy number increase occurred at a relatively high frequency in human HNSCC patient samples. CIP2A but not DPPA4 FISH status was significantly associated with patient survival. CIP2A detection by combining IHC with FISH yielded superior resolution in the prognostication of HNSCC. ConclusionsCIP2A copy number increase is associated with poor patient survival in human HNSCC. We suggest that the reliability and prognostic value of CIP2A detection can be improved by performing FISH analysis to CIP2A IHC positive tumours.en10.1111/jop.12372info:eu-repo/semantics/closedAccessCIP2ADPPA4head and neckin situ hybridisationprotein phosphatase 2asquamous cell carcinomaComparative Genomic HybridizationPrognostic IndicatorCancer CellsAmplificationProgressionStageGeneOverexpressionExpressionPp2aArticle455329337Q2WOS:0003741376000022-s2.0-8494623661126436875Q2